Tirzepatide dosing: what the trials used

Every published trial of tirzepatide uses the same basic dose architecture: a low starting dose, a stepped escalation over several weeks, then a maintenance dose held for the rest of the study. This page maps what those schedules looked like across the SURPASS (type-2 diabetes) and SURMOUNT (obesity) programmes, with footnotes to the primary publications.

This is an educational summary of published clinical data. It is not dosing guidance. Any decision about tirzepatide use belongs with a clinician who knows your full history.

The approved label: what it specifies

The Mounjaro prescribing information on DailyMed^[6] is the definitive reference for the FDA-approved schedule. The recommended starting dose is 2.5 mg subcutaneously once weekly. After four weeks, the dose increases to 5 mg weekly. From 5 mg, clinicians may increase in 2.5 mg increments at intervals of at least four weeks per step, up to a maximum of 15 mg weekly for adults. The full escalation ladder runs: 2.5 mg, then 5, 7.5, 10, 12.5, and 15 mg, each held at least four weeks before the next step.

Clinical trials pre-dated or ran alongside the label; their escalation schedules were fixed in the protocol but follow the same pharmacological logic: slow upward titration to reduce gastrointestinal adverse events during the period of peak receptor adaptation.

SURPASS programme: dosing in type-2 diabetes

SURPASS-1

SURPASS-1 (Rosenstock et al., Lancet 2021)^[3] enrolled 478 adults with type-2 diabetes inadequately controlled on diet and exercise alone, randomised to once-weekly tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, over 40 weeks. The trial was monotherapy: no background glucose-lowering medication. At 40 weeks, mean HbA1c fell by 1.87 percentage points on 5 mg, 1.89 on 10 mg, and 2.07 on 15 mg, against a 0.04 percentage point rise on placebo. Body weight fell 7.0 to 9.5 kg across the three active doses.

SURPASS-2

SURPASS-2 (Frias et al., NEJM 2021)^[4] was the head-to-head against semaglutide 1 mg in 1,879 adults with type-2 diabetes on background metformin, over 40 weeks. Tirzepatide was tested at 5 mg, 10 mg, and 15 mg once weekly. At 40 weeks, HbA1c fell by 2.01 percentage points on tirzepatide 5 mg, 2.24 on 10 mg, and 2.30 on 15 mg, against 1.86 on semaglutide 1 mg. All three tirzepatide doses were superior for glycaemic control. For body weight, tirzepatide 15 mg produced a 5.5 kg greater reduction than semaglutide 1 mg.

SURMOUNT programme: dosing in obesity trials

SURMOUNT-1

SURMOUNT-1 (Jastreboff et al., NEJM 2022)^[1] is the reference obesity trial. It enrolled 2,539 adults with obesity but without type-2 diabetes and randomised them to once-weekly tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, over 72 weeks. The protocol included a 20-week dose-escalation period before participants reached their assigned maintenance dose. At 72 weeks, mean body-weight reductions were 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, against 3.1% on placebo. Between 50% and 57% of participants on the higher doses achieved at least 20% weight loss, compared with 3% on placebo.

SURMOUNT-2

SURMOUNT-2 (Garvey et al., Lancet 2023)^[2] repeated the design in adults who also had type-2 diabetes, enrolling 938 participants (mean baseline weight 100.7 kg, mean HbA1c 8.02%). The trial tested 10 mg and 15 mg weekly over 72 weeks. Mean body-weight reductions were 12.8% on 10 mg and 14.7% on 15 mg, against 3.2% on placebo. Between 79% and 83% on tirzepatide achieved at least 5% weight loss versus 32% on placebo. The smaller figures relative to SURMOUNT-1 align with the attenuating effect of diabetes on GLP-1 class response seen across the incretin literature.

SURMOUNT-4: the discontinuation study

SURMOUNT-4 (Aronne et al., JAMA 2024)^[5] is the discontinuation trial. All participants spent a 36-week open-label lead-in on maximum tolerated tirzepatide (10 mg or 15 mg weekly), achieving a mean weight reduction of 20.9%. At week 36 they were randomised to continue tirzepatide or switch to placebo for 52 more weeks. From week 36 to 88, the tirzepatide group lost a further 5.5% on average; the placebo group regained 14.0%. Cumulative loss from baseline was 25.3% on continued tirzepatide and 9.9% on placebo. The trial is frequently cited for the evidence that tirzepatide functions as a chronic treatment rather than a short course.

Why the escalation schedule matters

Across every tirzepatide trial, gastrointestinal adverse events (nausea, diarrhoea, vomiting, constipation) were the principal reason for dose reduction or treatment discontinuation. These events are dose-dependent and concentrated in the escalation period. In SURMOUNT-1, discontinuation for adverse events ranged from 4.3% to 7.1% across tirzepatide groups, compared with 2.6% on placebo.

The stepped titration strategy used in trials (and formalised in the approved label) addresses this by giving the gastrointestinal system time to adapt before each dose increase. The four-week minimum between steps reflects a pharmacological judgement about the adaptation window, not an arbitrary calendar interval.

What the trials did not test

No published trial has tested tirzepatide below 2.5 mg weekly. The 2.5 mg starting dose is the floor of the evidence base. Doses above 15 mg weekly have not been tested in Phase 3. Twice-weekly dosing has not been compared with once-weekly in a controlled trial. And weight-loss durability beyond 88 weeks remains an open question. For a full account of what remains unknown, see the tirzepatide peptide page. For readers interested in how tirzepatide compares with semaglutide head-to-head, SURMOUNT-5 reported a 6.5 percentage point absolute weight-loss advantage for tirzepatide at 72 weeks.

Medical disclaimer

This article is for educational and journalistic purposes. PeptideMethods does not provide medical advice. All dosing information describes what published trials used or what the approved prescribing information states. It is not a protocol for readers to follow. Tirzepatide is a prescription medicine in every jurisdiction PeptideMethods covers. Any question about whether tirzepatide is appropriate, and at what dose, belongs with a qualified clinician.